Autolus Therapeutics (NASDAQ:AUTL) Trading 8.9% Higher

Autolus Therapeutics Ltd – (NASDAQ:AUTL) traded up 8.9% during trading on Friday . The company traded as high as $15.30 and last traded at $13.50, 292,800 shares were traded during mid-day trading. An increase of 71% from the average session volume of 170,856 shares. The stock had previously closed at $12.40.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. ValuEngine upgraded shares of Autolus Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $24.00 price target on shares of Autolus Therapeutics in a research note on Thursday. Finally, William Blair reiterated a “buy” rating on shares of Autolus Therapeutics in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $37.00.

The company has a debt-to-equity ratio of 0.09, a current ratio of 13.12 and a quick ratio of 13.12. The company has a market capitalization of $529.93 million, a PE ratio of -9.51 and a beta of 0.61. The stock’s 50 day simple moving average is $12.15 and its 200-day simple moving average is $19.78.



Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.11. The business had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $2.00 million. On average, equities analysts predict that Autolus Therapeutics Ltd – will post -3.11 earnings per share for the current year.

A number of large investors have recently modified their holdings of AUTL. Price T Rowe Associates Inc. MD increased its stake in Autolus Therapeutics by 120.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,180,396 shares of the company’s stock worth $19,004,000 after purchasing an additional 645,879 shares during the period. Marshall Wace LLP increased its stake in Autolus Therapeutics by 121.3% during the second quarter. Marshall Wace LLP now owns 515,405 shares of the company’s stock worth $8,298,000 after purchasing an additional 282,474 shares during the period. Renaissance Technologies LLC purchased a new stake in Autolus Therapeutics during the second quarter worth about $1,451,000. Citadel Advisors LLC purchased a new stake in shares of Autolus Therapeutics during the second quarter worth approximately $1,148,000. Finally, Sofinnova Investments Inc. purchased a new stake in shares of Autolus Therapeutics during the second quarter worth approximately $1,059,000. Institutional investors own 51.64% of the company’s stock.

About Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Featured Story: What are the benefits of a balanced fund?

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.